In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan

Kanayama, Shoji; Ikeda, Fumiaki; Okamoto, Kyoichi; Nakajima, Ayako; Matsumoto, Takuya; Ishii, Ritsuko; Amano, Ayako; Matsuzaki, Kaoru; Matsumoto, Satoru

doi:10.1016/j.jiac.2016.03.006

Cited by 17 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, ozenoxacin (OZN) is a more recent alternative for topical treatment of infection skin, with excellent clinical benefit in two recent Phase III trials [10]. OZN belongs to a new generation of non-fluorinated quinolones, demonstrating excellent antibacterial activity in vitro against Gram-positive cocci including resistant strains to other quinolones and low capacity to select resistant mutant strains [11–15].…”

Section: Introductionmentioning

confidence: 99%

Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis

et al. 2019

View full text Add to dashboard Cite

Ozenoxacin (OZN) belongs to a new generation of non-fluorinated quinolones for the topical treatment of skin infections which has shown to be effective in the treatment of susceptible and resistant Gram-positive cocci. The mutant prevention concentration (MPC) of ozenoxacin, levofloxacin and ciprofloxacin was determined in quinolone-susceptible and -resistant strains including methicillin-susceptible S. aureus, methicillin-resistant S. aureus, methicillin-susceptible S. epidermidis and methicillin-resistant S. epidermidis with different profile of mutation in the quinolone resistance determining regions (QRDR). The MPC value of OZN for the methicillin-susceptible S. aureus strain susceptible to quinolones, without mutations in QRDR, was 0.05 mg/L, being 280-fold lower than that observed with ciprofloxacin and levofloxacin. In methicillin-susceptible and–resistant S. aureus strains with mutations in the gyrA or/and grlA genes the MPC of OZN went from 0.1 to 6 mg/L, whereas the MPC of levofloxacin and ciprofloxacin was > 50 mg/L for the same strains. For methicillin-susceptible and–resistant S. epidermidis the results were similar to those abovementioned for S. aureus. According to our results, the MPC of OZN was far below the quantity of ozenoxacin achieved in the epidermal layer, suggesting that the in vivo selection of mutants, if it occurs, will take place at low frequency. Ozenoxacin is an excellent candidate for the treatment of bacterial infections caused by susceptible and quinolone-resistant staphylococci isolated usually from skin infections.

show abstract

Section: Introductionmentioning

confidence: 99%

Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In this study, approximately half of the cases were successfully treated with topical antibiotics alone, including cases positive for methicillin‐resistant Staphylococcus . Topical antibiotics such as nadifloxacin, sodium fusidate and ozenoxacin have activity against S. aureus , irrespective of the presence or absence of methicillin resistance . Therefore, topical antibiotics may be effective against superficial staphylococcal infection, while oral antibiotics may be needed for widespread folliculitis, furunculosis or lesions on a scalp with dense hair.…”

Section: Discussionmentioning

confidence: 99%

Clinical features and treatment of epidermal growth factor inhibitor‐related late‐phase papulopustular rash

Tohyama

Hamada

Harada

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Papulopustular rash, an acneiform rash, appears on the seborrheic region during the first to second week of treatment with an epidermal growth factor receptor inhibitor (EGFRi). The rash gradually disappears after the fourth week; however, it persists or newly develops in other regions during EGFRi treatment. Because Staphylococcus aureus is frequently isolated from late-phase papulopustular rash, we assessed the incidence of bacterial infection and treatment outcomes of patients with late-phase papulopustular rash. Sixty-four cases treated with an EGFRi over 4 weeks who presented with papulopustular rash were assessed retrospectively. The median duration of EGFR inhibitor treatment was 5 months. Grade 2 and 3 papulopustular rash was observed in 47 and eight cases, respectively. Bacterial culture was performed in 51 cases, 50 of which yielded positive results: methicillinsensitive S. aureus in 29, methicillin-resistant S. aureus in 14, Staphylococcus species in five, Pseudomonas aeruginosa in three, and other in four cases. Of the S. aureus isolates, 42% were resistant to minocycline and 40% to levofloxacin. After treatment with topical and/or oral antibiotics without topical corticosteroids, the papulopustular rash rapidly improved by an average of 2.9 AE 3.4 weeks. However, use of a combination of antibiotics and a topical corticosteroid prolonged the recovery period to an average of 18.9 AE 11.4 weeks. In conclusion, folliculitis that develops over 4 weeks after the initiation of EGFRi treatment is typically caused by staphylococcal infection. Bacterial culture is necessary due to the high rate of antibiotic resistance. It is important to distinguish late-from early-phase papulopustular rash and to treat using different approaches.

show abstract

“…As a result, it is exposed to and colonized by both pathogenic and non-pathogenic bacterial strains. Most of the skin surface-colonizing bacteria are gram-positive species including Staphylococcus aureus and Streptococcus pyogenes ( Kanayama et al, 2016 ). The normal flora in the skin provides protection against various pathogenic microflora, but the exact mechanism of interaction between the pathogenic and normal microflora in the skin is not well understood ( Grice & Segre, 2011 ).…”

Section: Discussionmentioning

confidence: 99%

Isolation, identification, and pathological effects of beach sand bacterial extract on human skin keratinocytesin vitro

Subhan

Shahzad

Tauseef

et al. 2018

PeerJ

View full text Add to dashboard Cite

BackgroundBeaches are recreational spots for people. However, beach sand contains harmful microbes that affect human health, and there are no established methods for either sampling and identifying beach-borne pathogens or managing the quality of beach sand.MethodThis study was conducted with the aim of improving human safety at beaches and augmenting the quality of the beach experience. Beach sand was used as a resource to isolate bacteria due to its distinctive features and the biodiversity of the beach sand biota. A selected bacterial isolate termed FSRS was identified as Pseudomonas stutzeri using 16S rRNA sequencing and phylogenetic analysis, and the sequence was deposited in the NCBI GenBank database under the accession number MF599548. The isolated P. stutzeri bacterium was cultured in Luria–Bertani growth medium, and a crude extract was prepared using ethyl acetate to examine the potential pathogenic effect of P. stutzeri on human skin. A human skin keratinocyte cell line (HaCaT) was used to assess cell adhesion, cell viability, and cell proliferation using a morphological analysis and a WST-1 assay.ResultThe crude P. stutzeri extract inhibited cell adhesion and decreased cell viability in HaCaT cells. We concluded that the crude extract of P. stutzeri FSRS had a strong pathological effect on human skin cells.DiscussionBeach visitors frequently get skin infections, but the exact cause of the infections is yet to be determined. The beach sand bacterium P. stutzeri may, therefore, be responsible for some of the dermatological problems experienced by people visiting the beach.

show abstract

In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan

Cited by 17 publications

References 9 publications

Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis

Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis

Clinical features and treatment of epidermal growth factor inhibitor‐related late‐phase papulopustular rash

Isolation, identification, and pathological effects of beach sand bacterial extract on human skin keratinocytesin vitro

Contact Info

Product

Resources

About